Despite heart disease being the leading cause of death in the U.S., millions lack access to affordable, accurate diagnostics. Peerbridge Health, the company transforming how heart disease is diagnosed, is working to close that gap and announced a series of milestones today that will move it closer to that goal. The company has closed its latest fundraising round and submitted its next-generation wearable, the Cor MDx™, for FDA 510(k) clearance. Additionally, Peerbridge Health has appointed Dan Reuvers, a medical-technology executive with decades of leadership experience, to its Board of Directors, and has expanded its sales team across three regions.
“We believe that lifesaving cardiac diagnostics should not be a luxury, yet access to affordable diagnostics is still out of reach for so many people,” said Chris Darland, CEO of Peerbridge Health. “Too many families delay or avoid cardiac testing because it’s either too expensive or not offered in their community. Whether you live in a rural town, a big city, or anywhere in between, our mission is to provide you with access to the same quality of care.”
The latest funding round raised $7M and will support Peerbridge’s commercial rollout of its latest generation product. The Cor MDx™ device represents a significant step forward in high-fidelity, real-time cardiac monitoring and is expected to launch later this year pending regulatory clearance.
The company also appointed Dan Reuvers to its Board of Directors. Dan brings over 30 years of leadership experience in the medical technology industry, having served as CEO of Tactile Medical, as well as president of the neuro division of Integra LifeSciences. He also serves on the board of directors of Etac. His proven ability to scale innovative health technology companies will make him an integral part of the team moving forward.
“Dan brings exactly the kind of experience we need right now as we move into this next phase,” said Chris Darland, CEO of Peerbridge Health. “His experience enriches our leadership team and we’re thrilled to officially welcome him to our board.”
Peerbridge’s growing sales force is now established in three regions with plans to expand their launch beyond these initial areas. This expansion will focus on bringing hospital-grade cardiac diagnostics into primary care and cardiology clinics with the goal of catching disease as early as possible, thus reducing ER visits and improving patient outcomes.
With these milestones, Peerbridge is advancing its mission to make high-quality, lifesaving cardiac diagnostics accessible to everyone. By combining cutting-edge technology with a focus on affordability, the company is working to close gaps in healthcare and ensure that early detection is available to every patient, everywhere.
